Table 2.

Small molecules shown to modulate H3S10ph deposition, FDA-approved for clinical trials

Name	Target	Clinical trial no	Phase	Disease	H3S10ph source
Barasertib (AZD1152-HQPA|AZD281)	AURKB/A	NCT03366675; NCT03217838	Phase 1/2	Small cell lung cancer, acute myeloid leukemia /high-risk myelodysplastic syndrome, advanced solid tumors	[149]
Flavopiridol	CDKs, including CDK8	NCT03593915; NCT03441555; NCT03563560	Phase 1/2	Myelodysplastic syndromes; acute myeloid leukemia	[150, 151]
BI-847325	AURKA/B/C	NCT01324830	Phase 1	Solid tumors	[152]
Alisertib	AURKA	NCT02860000	Phase 2	Breast cancer	[91]
SEL120	CDK8	NCT04021368	Phase 1	Acute myeloid leukemia or high-risk myelodysplastic syndrome	[153] and unpublished observations
SEL24/MEN1703	PIM kinases	NCT03008187	Phase 1/2	Acute myeloid leukemia	[154]
PIM447	PIM kinases	NCT02370706	Phase 1	Myelofibrosis	[62, 63]